Pay in 4 interest-free payments of $6.15 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Some researchers report fatigue during the adjustment period, similar to GLP-1-related fatigue seen with other medications
Neuroscience 249, 162171 (2013)
References Jastreboff AM, et al, Triple-Hormone-Receptor Agonist Retatrutide for Obesity, a Phase 2 Trial, New England Journal of Medicine, 2023 Bajaj HS, et al, Efficacy and Safety of Retatrutide in Type 2 Diabetes, TRANSCEND-T2D-1, a Phase 3 Trial, The Lancet, 2026 Giblin K, Kaplan LM, Somers VK, et al, Retatrutide for the Treatment of Obesity, Obstructive Sleep Apnea and Knee Osteoarthritis, Rationale and Design of the TRIUMPH Registrational Clinical Trials, Diabetes, Obesity and Metabolism, 2026 ClinicalTrials.gov, TRIUMPH-1 trial registry entry, NCT05929066 Eli Lilly and Company, TRIUMPH-1 Phase 3 topline results announcement, May 2026 Eli Lilly and Company, TRIUMPH-4 Phase 3 trial results announcement, December 2025 Eli Lilly and Company, TRANSCEND-T2D-1 Phase 3 topline results announcement, March 2026 Central Drugs Standard Control Organisation, Subject Expert Committee meeting record on retatrutide Phase 3 trial permission, 2024 Medically reviewed by This guide was checked for medical accuracy by our review board before publishing
Beinaglutide for weight management in Chinese individuals with overweight or obesity: a phase 3 randomized controlled clinical study
Overview In this article, we understand that navigating your weight loss journey can be challenging, and were here to support you every step of the way
US$ 22.69
US$ 27.33
US$ 28.90
US$ 21.79
